Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2
暂无分享,去创建一个
A. Al-Chalabi | P. Leigh | C. Garlanda | H. Zetterberg | J. de Vos | Dennis Wang | U. Andréasson | P. Heath | J. Kirby | P. Shaw | J. Veyrune | W. Camu | M. Locati | G. Bensimon | S. Saker | T. Tree | C. Payan | N. Bayatti | A. Malaspina | C. Suehs | N. Pageot | Christophe Masseguin | Abigail Brown | M. Mickunas | R. Juntas-Morales | I. Giovannelli | U. Andreasson | P. Shaw
[1] A. Al-Chalabi,et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial , 2020, EBioMedicine.
[2] P. Heath,et al. The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therapeutic potential , 2020, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[3] T. Woodruff,et al. The Peripheral Immune System and Amyotrophic Lateral Sclerosis , 2020, Frontiers in Neurology.
[4] C. Limatola,et al. Natural killer cells modulate motor neuron-immune cell cross talk in models of Amyotrophic Lateral Sclerosis , 2020, Nature Communications.
[5] T. Ziemssen,et al. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis , 2020, Scientific Reports.
[6] S. Appel,et al. Increased activation ability of monocytes from ALS patients , 2020, Experimental Neurology.
[7] T. Woodruff,et al. Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis , 2020, Brain communications.
[8] Yoon-Ho Hong,et al. High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis , 2020, Scientific Reports.
[9] S. Wilton,et al. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? , 2019, Front. Neurosci..
[10] P. Shaw,et al. Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration , 2019, Brain : a journal of neurology.
[11] J. Alexander,et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial , 2019, Annals of the rheumatic diseases.
[12] J. Kopchick,et al. ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia , 2019, Journal of Translational Medicine.
[13] F. Granucci,et al. Below the surface: The inner lives of TLR4 and TLR9 , 2019, Journal of leukocyte biology.
[14] T. Malek,et al. Essential and non-overlapping IL-2Rα-dependent processes for thymic development and peripheral homeostasis of regulatory T cells , 2019, Nature Communications.
[15] G. Riemekasten,et al. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus , 2019, Current opinion in rheumatology.
[16] C. Raoul,et al. Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons , 2019, Proceedings of the National Academy of Sciences.
[17] Farzane Sivandzade,et al. NRF2 and NF-қB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches , 2018, Redox biology.
[18] B. Fiebich,et al. Role of Microglia TLRs in Neurodegeneration , 2018, Front. Cell. Neurosci..
[19] E. Erba,et al. Counteracting roles of MHCI and CD8+ T cells in the peripheral and central nervous system of ALS SOD1G93A mice , 2018, Molecular Neurodegeneration.
[20] G. Stewart,et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model , 2018, JAMA neurology.
[21] Ahmad Al Khleifat,et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study , 2018, The Lancet Neurology.
[22] Amit Sharma,et al. Emerging Functions of Regulatory T Cells in Tissue Homeostasis , 2018, Front. Immunol..
[23] Stephen A. Goutman,et al. Amyotrophic lateral sclerosis , 2022, Nature Reviews Disease Primers.
[24] L. Beckers,et al. CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice , 2017, European Heart Journal.
[25] H. Sasaki,et al. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[26] Jia Liu,et al. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications , 2017, Front. Immunol..
[27] N. Staff,et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis , 2017, PloS one.
[28] Y. Itoyama,et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet Neurology.
[29] Shanker Kalyana-Sundaram,et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes , 2017, JAMA neurology.
[30] E. Shpall,et al. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. , 2017, JCI insight.
[31] Robert H. Brown,et al. Decoding ALS: from genes to mechanism , 2016, Nature.
[32] R. Başar,et al. A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. , 2016, Cytotherapy.
[33] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[34] E. Hovig,et al. Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses , 2015, Biostatistics.
[35] DelindaA . Johnson,et al. Nrf2--a therapeutic target for the treatment of neurodegenerative diseases. , 2015, Free radical biology & medicine.
[36] M. Fehlings,et al. Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside , 2015, Molecules.
[37] D. Klatzmann,et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. , 2015, Journal of autoimmunity.
[38] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[39] Thomas E. Hughes,et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[40] P. Bahadoran,et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. , 2014, JAMA dermatology.
[41] J. Melenhorst,et al. Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity , 2014, Clinical Cancer Research.
[42] Andreas Krämer,et al. Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..
[43] D. Klatzmann,et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. , 2013, The lancet. Diabetes & endocrinology.
[44] A. Higginbottom,et al. S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis☆ , 2013, Free radical biology & medicine.
[45] S. Appel,et al. Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis , 2013, Journal of Neuroimmune Pharmacology.
[46] E. Chen,et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.
[47] D. Pennington,et al. Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27–CD70 pathway , 2013, The Journal of experimental medicine.
[48] S. Powell,et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival , 2012, EMBO molecular medicine.
[49] S. Appel,et al. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms , 2012, Neurobiology of Disease.
[50] C. Schürch,et al. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. , 2012, Cancer research.
[51] I. Evdokimidis,et al. Alterations of T cell subsets in ALS: a systemic immune activation? , 2012, Acta neurologica Scandinavica.
[52] F. Carrat,et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.
[53] J. Ritz,et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.
[54] Michael Sendtner,et al. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis , 2011, Nature Reviews Neurology.
[55] Matko Bosnjak,et al. REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.
[56] T. Malek,et al. T‐cell tolerance and the multi‐functional role of IL‐2R signaling in T‐regulatory cells , 2011, Immunological reviews.
[57] S. Appel,et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis , 2011, Brain : a journal of neurology.
[58] P. Shaw,et al. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. , 2010, Free radical biology & medicine.
[59] G. Mora,et al. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process , 2009, Journal of Neuroimmunology.
[60] W. Schulz-Schaeffer,et al. Screening of innate immune receptors in neurodegenerative diseases: A similar pattern , 2009, Neurobiology of Aging.